| Wang, Nan |
NCT06200766: A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis |
|
|
| Recruiting | 3 | 640 | RoW | Mometasone furoate as a nasal spray | Zheng Liu ENT, Zhejiang Xianju Pharma Tech. Co., Ltd | Seasonal Allergic Rhinitis | 04/24 | 06/24 | | |
NCT06475417: Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 42 | RoW | Adebrelimab combined with DOS | Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Gastric Cancer | 05/25 | 04/26 | | |
| Not yet recruiting | N/A | 60 | RoW | Endostar, S1 | Peking University Third Hospital, Mianyang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Cancer Hospital, Peking University International Hospital, China-Japan Friendship Hospital, The fifth medical center of PLA general hospital, Second Hospital of Shanxi Medical University, Hiser Medical Center of Qingdao, Guangxi Ruikang Hospital, GEM flower hospital of Liaohe oil field, Tang-Du Hospital, Third Affiliated Hospital of Guizhou Medical University, Liuzhou Worker's Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian municipal central hospital affiliated of dalian medical university | Radiotherapy Side Effect | 01/22 | 01/23 | | |
NCT06484764: Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure. |
|
|
| Completed | N/A | 166 | RoW | CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions, Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions | Tianjin Medical University Cancer Institute and Hospital, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Wuhan United Imaging Healthcare-Surgical Technology Co., Ltd. Wuhan, China | Abdominal Cancer, Thoracic Cancer | 10/23 | 11/23 | | |
NCT05715632: New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX |
|
|
| Recruiting | N/A | 46 | RoW | Carrelizumab combined with XELOX | Tang-Du Hospital | Gastric Cancer | 03/24 | 03/25 | | |
NCT06370468: The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis |
|
|
| Recruiting | N/A | 150000 | RoW | Epidemiological investigation | Zheng Liu ENT, Peking Union Medical College, Hainan People's Hospital, Shandong Second Provincial General Hospital, First Affiliated Hospital of Chongqing Medical University, First Affiliated Hospital of Xinjiang Medical University | Chronic Rhinitis | 05/27 | 08/27 | | |
NCT05418920: Clinical Trial of Reconstruction After Proximal Gastrectomy |
|
|
| Not yet recruiting | N/A | 250 | NA | left-opening single-flap technique, double-flap group technique | Oncogastroenterology Committee of Chinese, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, General Hospital of Ningxia Medical University, Henan Provincial People's Hospital, The First Affiliated Hospital of Shanxi Medical University | Esophagitis, Reflux | 07/24 | 07/27 | | |
NCT05279612: Effect Analysis of Neoadjuvant Chemoradiotherapy Combined With Surgery in Laparoscope for Advanced Colon Cancer |
|
|
| Active, not recruiting | N/A | 177 | RoW | Short-term neoadjuvant chemoradiotherapy | Tang-Du Hospital | Colon Neoplasm | 10/24 | 05/25 | | |
| Jiang, Tao |
NCT04934059: Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). |
|
|
| Not yet recruiting | 4 | 60 | RoW | Yuxuebi tablet, Placebo tablet | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | Ankylosing Spondylitis | 01/22 | 01/22 | | |
pcwaintrl, NCT05387109: Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 41 | NA | penpulimab combined with anlotinib | Tang-Du Hospital | NSCLC | 04/23 | 04/24 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT05388825: Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction |
|
|
| Completed | 2 | 84 | RoW | TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg, Placebo 5mg, Placebo 10mg | Vigonvita Life Sciences | Erectile Dysfunction | 01/23 | 02/23 | | |
NCT05055583: Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab in Combination With Platinum-based Chemotherapy, Toripalimab Injection, JS001, Teruipuli Dankang, TuoYI, Surgical treatment stage, Adjuvant treatment stage | Tang-Du Hospital | NSCLC Stage IV, Oligometastasis | 08/23 | 12/23 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 60 | RoW | 210mg of TQC2731 injection, 420mg of TQC2731 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 05/25 | 02/26 | | |
NCT06663059: Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study |
|
|
| Recruiting | 2 | 80 | RoW | Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle, Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle | Tang-Du Hospital | Esophageal Cancer | 12/25 | 09/27 | | |
NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 80 | RoW | TQC2731 injection, TQC2731 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Sinusitis, Nasal Polyps | 07/25 | 09/25 | | |
NCT05124951: The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors |
|
|
| Recruiting | 2 | 150 | RoW | Whole-ventricle irradiation, Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide, Second-look surgery | Beijing Tiantan Hospital | Intracranial Germ Cell CNS Tumor, Childhood | 10/26 | 10/26 | | |
NCT06006650: Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell |
|
|
| Recruiting | 2 | 114 | RoW | Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin | Tang-Du Hospital | Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma | 12/31 | 12/31 | | |
NCT05577091: Tris-CAR-T Cell Therapy for Recurrent Glioblastoma |
|
|
| Recruiting | 1 | 10 | RoW | Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes., Autologous Tris-CAR-T cell. | Beijing Tiantan Hospital, Beijing Neurosurgical Institute, Tasly Pharmaceutical Group Co., Ltd | Recurrent Glioblastoma | 11/24 | 11/32 | | |
ATM, NCT04706338: Transcranial Magnetic Stimulation in the Rehabilitation of Postoperative Motor Dysfunction. |
|
|
| Recruiting | N/A | 30 | RoW | TMS treatment | Beijing Neurosurgical Institute | Glioma, Postoperative Motor Deficit | 06/21 | 01/22 | | |
| Recruiting | N/A | 100 | RoW | the Cover group, the Fill group, the peeling group | Second Affiliated Hospital, School of Medicine, Zhejiang University | Macular Holes | 06/21 | 09/21 | | |
| Recruiting | N/A | 60 | RoW | | Beijing Neurosurgical Institute | Gliomas | 01/22 | 01/25 | | |
| Recruiting | N/A | 135 | RoW | LITT, Control | Beijing Tiantan Hospital | Recurrent High Grade Glioma | 03/26 | 09/27 | | |
NCT05143788: Strategic Intervention on Preserving Motor Function During Awake Craniotomy |
|
|
| Not yet recruiting | N/A | 60 | NA | Awake craniotomy | Beijing Neurosurgical Institute, Beijing Tiantan Hospital | Glioma | 12/23 | 12/23 | | |
NCT05803057: Accelerating Motor Recovering in Patients With SMA Syndrome After Glioma Surgery by Using nrTMS |
|
|
| Recruiting | N/A | 64 | RoW | TMS stimulation treatment, TMS stimulation sham-treatment | Beijing Neurosurgical Institute | Motor Cortex; Lesion, Glioma, Supplementary Motor Area Syndrome | 03/24 | 03/25 | | |
NCT05901844: Evaluate the Accuracy of Raman IVD Analyzer in the Diagnosis of Gliomas During Surgery |
|
|
| Not yet recruiting | N/A | 256 | NA | Paraffin pathological diagnosis, Raman analyzer diagnosis | Beijing Tiantan Hospital, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Capital Medical University, Jiangsu Raman Medical Equipment Co., Ltd. | Glioma | 06/24 | 10/24 | | |
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China |
|
|
| Recruiting | N/A | 12000 | RoW | no intervention | Zhujiang Hospital, National Natural Science Foundation of China | Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism | 12/24 | 12/25 | | |
NCT04425798: Connectivity Alterations After Levetiracetam Application |
|
|
| Not yet recruiting | N/A | 30 | RoW | | Beijing Neurosurgical Institute, Beijing Tiantan Hospital | Glioma, Epilepsy | 05/22 | 09/22 | | |
NCT05167604: Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC |
|
|
| Recruiting | N/A | 150 | RoW | Adjuvants, Pharmaceutic, adjuvant chemotherapy | Tang-Du Hospital | Carcinoma, Non-Small-Cell Lung, Next-Generation Sequencing, Chemotherapy, Adjuvant, Neoplasm, Residual, Circulating Tumor DNA | 09/23 | 12/24 | | |
NCT05124964: Prospective Study on Quality of Life in Patients With Intracranial Germ Cell Tumors |
|
|
| Recruiting | N/A | 150 | RoW | PedsQL 4.0 Scale, PedsQL 4.0 Generic Core Scale, Short Form-36, SF-36, Chinese Wechsler Intelligence Scale for Children, C-WISC | Beijing Tiantan Hospital | Quality of Life | 10/26 | 10/26 | | |
GRIPP, NCT05672043: Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China |
|
|
| Recruiting | N/A | 400 | RoW | | Beijing Tiantan Hospital | Medulloblastoma, Central Nervous System Tumor, Pediatric, Ependymoma, Germ Cell Tumor, Glioma, Brain Tumor, Pediatric | 12/27 | 12/32 | | |
| Min, Jie |
NCT06467786: Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer |
|
|
| Recruiting | 4 | 24 | RoW | Irinotecan hydrochloride liposome injection | Tang-Du Hospital | Small Cell Lung Cancer | 09/25 | 09/28 | | |
NCT06475209: Adebrelimab + Apatinib in SCLC Maintenance Therapy |
|
|
| Recruiting | 2 | 60 | RoW | Adebrelimab combined with Apatinib | Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | SCLC | 12/25 | 12/26 | | |
NCT06352502: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis |
|
|
| Recruiting | N/A | 30 | RoW | Furmonertinib, AST2818 | Tang-Du Hospital | EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases | 09/24 | 09/24 | | |
| yan, xiaolong |
TERMGGO, NCT04982900: Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities |
|
|
| Recruiting | 2 | 138 | RoW | furmonertinib, AST2818, Placebo | Ruijin Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Multiple Primary Lung Cancers | 08/22 | 08/22 | | |
NCT05400070: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC |
|
|
| Active, not recruiting | 2 | 45 | RoW | Neoadjuvant therapy 1, anlotinib 10mg, po, qd1-14, q3w, Chemotherapy, Sintilimab (200mg fixed dose) iv, d1, q3w | Tang-Du Hospital | Sintilimab, Lung Cancer, Anlotinib, Chemotherapy | 12/23 | 12/26 | | |
NO.202405-11, NCT06475755: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC |
|
|
| Not yet recruiting | 2 | 178 | RoW | Immunochemotherapy combined with antiangiogenic, Tislelizumab, Anlotinib, Cisplatin, Carboplatin, Paclitaxel, Albumin-bound paclitaxel, Pemetrexed, Immunochemotherapy | Tang-Du Hospital | Non-Small Cell Lung Cancer, Anti Angiogenesis | 06/25 | 12/27 | | |
NCT06485544: Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial |
|
|
| Recruiting | 2 | 104 | RoW | Adebrelimab + Etoposide + Platinum-based Therapy, Etoposide + Platinum-based Therapy | Tang-Du Hospital | Small Cell Lung Cancer (SCLC) | 12/25 | 12/26 | | |
NCT06006650: Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell |
|
|
| Recruiting | 2 | 114 | RoW | Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin | Tang-Du Hospital | Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma | 12/31 | 12/31 | | |
NCT06644066: Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane |
|
|
| Recruiting | N/A | 60 | RoW | Partial pressure of Oxygen Control method | Tang-Du Hospital | Lung Cancer | 07/24 | 12/24 | | |
NCT06028412: Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5 |
|
|
| Enrolling by invitation | N/A | 660 | RoW | Sublobar, Lobectomy | Xiaolong Yan, Dr. | NSCLC, Stage I | 12/29 | 12/30 | | |
